News

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Fierce Healthcare2d
New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200
Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...
Modern Healthcare2d
Cigna debuts GLP-1 copay cap
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...
Healthcare Dive1d
Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
Devdiscourse2d
Cigna Lowers Out-of-Pocket Costs for Popular Weight-Loss Drugs
Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...
GlobalData on MSN2d
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...
Zacks Investment Research on MSN22h
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...